Evaluation of XRCC-1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiotherapy

Correlation of XRCC-1 Arg194Trp polymorphismwith outcome in HNSCC patients treated with CCRTwas evaluatedin 101 patients [wild (62), polymorphic variants (39)].Polymorphic variant had higher grade > 2 mucositis (p=0.023), laryngeal toxicity (p=0.006) and dermatitis (p=0.003).2-year PFS rate for patients with polymorphic vs. wild variant was 57% vs. 42.2% (p= 0.076).Polymorphic variant HNSCC treated with CCRT have increased acute radiation morbidities and possibly better PFS.

https://ift.tt/2GIflmq